题名

Clobazam-induced Stevens-Johnson Syndrome Associated with HLA-B*1502

并列篇名

Clobazam誘發史蒂芬強生症候群與HLA-B*1502之相關

作者

黃美鳳(Mei-Feng Huang)；劉黛玲(Tai-Ling Liu)；葉怡君(Yi-Chun Yeh)；陳正生(Cheng-Sheng Chen)

关键词
期刊名称

台灣精神醫學

卷期/出版年月

32卷2期（2018 / 06 / 01）

页次

171 - 172

内容语文

英文
主题分类 醫藥衛生 > 社會醫學
参考文献
  1. Chang, CJ(2011).Genotyping HLA-B*1502 and revised drug hazard relief act.Taiwanese Journal of Psychiatry,25,123-125.
    連結：
  2. Arif, H,Buchsbaum, R,Weintraub, D(2007).Comparison and predictors of rash associated with 15 antiepileptic drugs.Neurology,68,1701-1709.
  3. Chung, WH,Hung, SI,Hong, HS(2004).Medical genetics: a marker for Stevens-Johnson syndrome.Nature,428,486.
  4. Ertam, I,Sezgin, AO,Unal, I(2009).A case with Stevens Johnson syndrome triggered by combination of clobazam, lamotrigine, and valproic acid treatment.Int J Dermatol,48,98-99.
  5. Rattanavipapong, W,Koopitakkajorn, T,Praditsitthikorn, N,Mahasirimongkol, S,Teerawattananon, Y(2013).Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand.Epilepsia,54,1628-1638.
  6. Wieck, HH,Blaha, L,Heerklotz, B(1979).A clinical view of clobazam.Br J Clin Pharmacol,7(Suppl 1),109S-112S.
print cancel